Abrdn Life Sciences Investors Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Chris Lavictoire Mahai, a Director of abrdn Life Sciences Investors, purchased 527 shares of common stock on July 16, 2026 for $19.92 per share.
NYSE
abrdn Life Sciences Investors Director Christian Pittard reported a planned purchase of 7,923 common stock shares at $16.8818, scheduled for December 16, 2025, under a Rule 10b5-1 plan.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors, reported sales of common stock totaling 48,612 shares.
NYSE
Saba Capital Management, L.P., a 10% owner of abrdn Life Sciences Investors, reported the sale of 64,536 shares of common stock in mid-September 2025.
NYSE
Saba Capital Management, a 10% owner and director, reported sales of abrdn Life Sciences Investors common stock totaling 2,726 shares in mid-September 2025.
NYSE
Form 4: Saba Capital Sells HQL Shares
Saba Capital Management, a 10% owner and director of abrdn Life Sciences Investors (HQL), reported selling 15,116 shares of common stock.
NYSE
Saba Capital Management, a 10% owner and director, reported selling 14,083 shares of abrdn Life Sciences Investors common stock.
NYSE
Saba Capital Management, a 10% owner and director, reported the sale of 23,723 shares of abrdn Life Sciences Investors common stock at $13.89 per share.
NYSE
Saba Capital Management, a 10% owner and director, reported the sale of 400 abrdn Life Sciences Investors common shares at $13.83 per share.
NYSE
Saba Capital Management, a 10% owner and director, reported the pre-planned sale of 10,710 shares of abrdn Life Sciences Investors common stock at $14.07 per share.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors, reports the sale of 11,419 shares of common stock at $12.71 per share on May 20, 2025.
NYSE
Saba Capital Management reports the disposition of 23,729 shares of abrdn Life Sciences Investors at a price of $12.08 per share on May 15, 2025.
NYSE
Saba Capital Management reports selling shares of abrdn Life Sciences Investors, decreasing their beneficial ownership.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors, disposed of 12,689 shares of common stock at a price of $11.98 on May 8, 2025.
NYSE
Saba Capital Management reports a sale of abrdn Life Sciences Investors stock, decreasing its holdings.
NYSE
Saba Capital Management, a 10% owner and director of abrdn Life Sciences Investors, disposed of 9,144 shares of common stock at a price of $11.78 on April 17, 2025.
NYSE
Saba Capital Management, a 10% owner and director of abrdn Life Sciences Investors, disposed of 1,700 shares of common stock at a price of $11.92 on April 15, 2025.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), reported the purchase of 15,400 shares of common stock at $11.67 per share on April 14, 2025.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors, disposed of 30,156 shares of common stock at a price of $11.14 on April 10, 2025.
NYSE
Saba Capital Management reports selling shares of abrdn Life Sciences Investors, decreasing their beneficial ownership.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), has decreased its holdings through recent stock sales.
NYSE
Saba Capital Management reports a disposition of shares in abrdn Life Sciences Investors, reducing its beneficial ownership.
NYSE
Saba Capital Management reports a decrease in its beneficial ownership of abrdn Life Sciences Investors (HQL) common stock following recent transactions.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), reported the sale of 2,329 shares of common stock at a price of $13.21 on March 24, 2025.
NYSE
Saba Capital Management reports a disposition of shares in abrdn Life Sciences Investors, decreasing its holdings.
NYSE
Saba Capital Management, a 10% owner and director in abrdn Life Sciences Investors, disposed of 100 shares of common stock at a price of $13.88 on February 13, 2025.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), disposed of 36,536 shares of common stock at a price of $13.75 per share on February 12, 2025.
NYSE
Saba Capital Management, a 10% owner and director in abrdn Life Sciences Investors, reports selling shares of common stock over two days.
NYSE
Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), has reported selling shares of common stock on February 3rd and 4th, 2025.
NYSE
Saba Capital Management, a significant shareholder, has decreased its holdings in abrdn Life Sciences Investors through recent transactions.